Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Liabilities and Shareholders Equity (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $114.9 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 50.78% to $114.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $321.5 million through Dec 2025, up 4.91% year-over-year, with the annual reading at $114.9 million for FY2025, 50.78% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $114.9 million at Orchestra BioMed Holdings, up from $104.8 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $161.6 million in Q2 2022, with the low at $42.8 million in Q2 2025.
  • Average Liabilities and Shareholders Equity over 4 years is $99.3 million, with a median of $95.4 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity soared 69.5% in 2023, then tumbled 42.5% in 2024.
  • Over 4 years, Liabilities and Shareholders Equity stood at $95.6 million in 2022, then fell by 0.38% to $95.2 million in 2023, then decreased by 20.0% to $76.2 million in 2024, then surged by 50.78% to $114.9 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $114.9 million, $104.8 million, and $42.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.